AbstractBySubCategory

Multidisciplinary Treatment

Cancers of the Esophagus and Stomach

2017 Gastrointestinal Cancers Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. Karyn A. Goodman

01

Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. Yoon-Koo Kang

02

A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Salah-Eddin Al-Batran

04

Primary results of a phase III trial to evaluate bursectomy for patients with subserosal/serosal gastric cancer (JCOG1001). Masanori Terashima

05

A prospective multicenter observational study of surgical palliation examining postoperative quality of life in patients treated for malignant gastric outlet obstruction caused by incurable advanced gastric cancer. Kazumasa Fujitani

06

Survival results of a multicenter phase II study of trastuzumab with S-1 alone in elderly patients with HER-2 positive advanced gastric cancer (JACCRO GC-06). Kazuhiro Nishikawa

100

Post-gastrectomy nutrition risk index can be a good predictive factor for survival. Keiichi Fujiya

101

Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). Ian Chau

102

Upfront surgery, neoadjuvant, and definitive chemoradiation for clinical T2N0 esophageal adenocarcinoma: A propensity score matched analysis from the National Cancer Database analysis. Ravi Shridhar

103

Risk of peritoneal carcinomatosis in localized gastric adenocarcinoma patients who undergo preoperative therapy and attempted surgery. Dilsa Mizrak Kaya

104

Pathologic nodal response in gastric cancer: Do all patients need adjuvant therapy? Brandon George Smaglo

107

Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 and mFOLFOX6 in patients with advanced gastric/gastroesophageal junction cancer. Manish A. Shah

108

Potentially preventable readmissions after complex cancer surgery: Analysis of the national readmissions dataset. Syed Nabeel Zafar

109

New tyrosine kinase inhibitors in the treatment of Imatinib resistant GIST: An updated meta-analysis. Fiorella Pendola

110

Impact of current “insufficient” clinical nodal staging on treatment decisions and response to neoadjuvant chemoradiotherapy in esophageal cancer patients. Willemieke P.M. Dijksterhuis

111

Phase II study of S-1 plus oxaliplatin (OX) at dose of 130 mg/m2 (SOX130) in Japanese patients (pts) with advanced gastric cancer (AGC). Yosuke Kito

112

Influence of tumor response and treatment schedule on the distribution of tumor recurrence in esophageal cancer patients treated with neoadjuvant chemoradiotherapy. Kristien M. Jipping

113

Outcomes of definitive radiotherapy (dRT) and chemo-radiotherapy (dCRT) for loco-regionally confined (LRC) adenocarcinoma (ACA) of the esophagus and gastro-esophageal junction (E/GEJ). Vidhya Karivedu

114

Randomized phase II study of TJ-54 (Yokukansan) for postoperative delirium in gastrointestinal malignancy patients. Mariko Kamiya

115

Predictors of survival after trimodality therapy for esophageal adenocarcinoma: Analysis from the National Cancer Database. Oliver Eng

116

Phase II trial of adjuvant immunotherapy with autologous tumor-derived Gp96 vaccination in patients with gastric cancer. Lin Chen

117

Serial monitoring of imatinib pharmacokinetics (PK) in perioperative imatinib treatment in patients (pts) with gastrointestinal stromal tumors (GISTs): Results from the multinational phase II trial. Changhoon Yoo

118

Recurrence patterns of gastric cancer in the era of preoperative therapy. Naruhiko Ikoma

119

Standard personalized medicine platform integrating clinical genomics and patient-derived xenograft models for gastric cancer. Han-Kwang Yang

120

ARDS in the setting of FOLFOX/cetuximab based chemoradiotherapy for locally advanced esophageal adenocarcinoma (E2205). Ramla NAMISANGO Kasozi

121

Postoperative mortality after esophageal and gastric cancer surgery: Does age still matter? Results from a nationwide study. Christophe Mariette

122

Retrospective review of subsequent treatments (tx) for esophagogastric adenocarcinomas (EGA) refractory to FOLFOX. Ciara Marie Kelly

123

Gastrointestinal stromal tumors: Immune protein expression and clinical outcomes. Andrew M. Blakely

124

Short and long term outcomes with robotic assisted esophagectomy. Kenneth L Meredith

125

Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre. Hao-Wen Sim

126

Gastrectomy after chemotherapy: A new paradigm for the treatment of stage IV gastric cancer. Ho Seok Seo

127

A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer. Rui-hua Xu

128

Phase II study of S-1 plus docetaxel as first-line treatment for elderly patients with advanced gastric cancer (OGSG0902). Jin Matsuyama

129

Is three years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up. JianXian Lin

130

Attenuation of the volume-outcome relationship for gastrointestinal cancer surgery over time: Is a push towards continued regionalization justified? Nabil Wasif

131

Quality of life (QOL) in esophageal cancer patients treated with tri-modality therapy: Is the CROSS protocol better? Rachel Woo

132

Prospective randomized crossover study of effects of traditional Japanese herbal medicine rikkunshito on food intake and plasma acylated ghrelin levels in patients with esophageal cancer administered with cisplatin-based chemotherapy. Yoichi Hamai

133

Volumetric changes of the primary esophageal tumor during radiation therapy. Brady Laughlin

134

Impact of squamous histology on the response to treatment and long-term outcomes of patients with distal esophageal cancer. Parth Kishore Shah

135

Treatment trends in gastroesophageal and gastric cancers in the United States. Ali Mokdad

136

The impact of proton beam therapy on blood cell count nadir during neoadjuvant chemoradiation therapy for esophageal cancer. Yutaka Shiraishi

137

A National Cancer Database analysis of treatment utilization and associated outcomes in elderly patients with locally advanced esophageal cancer. Gregory Riccardo Vlacich

138

Checkpoint expression pre and post chemoradiation in operable esophageal cancer. Ronan Joseph Kelly

139

Cisplatin/5-fluorouracil (CF) versus carboplatin/paclitaxel (CT) chemoradiotherapy (CRT) for locoregionally advanced esophageal cancer (LAEC). Michael Marquardt

140

Impact of sarcopenia on survival outcomes in patients (pts) with metastatic gastric cancer (mGC). Keiji Sugiyama

141

Comparison between local and extended field radiotherapy, including regional nodes radiotherapy, in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer. Yukihiro Nakatani

142

Outcomes of locoregional therapy for metastatic gastric cancer. Ravi Shridhar

143

Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma. Do Hoon Kim

144

Exclusive chemoradiation with carboplatin-paclitaxel versus FOLFOX-4 in locally advanced esophageal cancer: A matched-pair analysis. Joelle Miny

145

Patterns of treatment and outcomes in elderly patients with non-metastatic, unresected gastric adenocarcinoma: A review of the Florida cancer data system. Gregory Riccardo Vlacich

146

Effect of nodal status compared to tumor response after neoadjuvant radiation on outcomes for patients with esophageal cancer. Sushanth Reddy

147

Trends in multimodality therapy for gastric cancer post-MAGIC. Yvonne Sada

148

Phase I study of neoadjuvant chemotherapy with xeloda and oxaliplatin (G-XELOX) for locally advanced gastric cancer. Hironaga Satake

149

Surgically treated esophageal cancer developed in a radiated field: Impact on peri-operative and long-term outcomes. Christophe Mariette

150

Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205. Yasuyuki Kawamoto

151

Conversion surgery for unresectable gastric cancer following complete response of distant metastasis by systemic chemotherapy. Daisuke Kobayashi

152

Geographic and site variability in the treatment of patients with metastatic gastric cancer. Lisa M. Hess

153

Efficacy and safety of taxane-monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: A multicenter retrospective study. Sadayuki Kawai

154

Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care. Kishan Shani

155

Impact of a pre- and postoperative chemotherapy (Ctx) on overall survival (OS) and progression free survival (PFS) in locally advanced gastric cancer (LAGC). Ricarda Manth

156

A multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with advanced gastric cancer. Tetsuji Terazawa

157

The prognostic factors for advanced gastric cancer with para-aortic nodal involvement after extended gastrectomy. Akio Kaito

158

Quality of life and self-management strategies after gastroesophageal cancer surgery. Virginia Sun

159

Converting borderline-resectable, locally-advanced esophageal carcinoma to resectability with neoadjuvant chemoradiotherapy. Zachary D. Horne

160

Biomarker studies in a phase I trial of DKN-01 in advanced esophageal cancer. John H. Strickler

161

Positive radial resection margin after esophagectomy for esophageal cancer patients treated at a tertiary center and its impact on survival. Parth Kishore Shah

162

Trends in utilization of chemotherapy and radiation for resectable gastric adenocarcinoma: An NCDB analysis. Benjamin Mitchell Motz

163

Superior prognosis prediction performance of deep learning for gastric cancer compared to Yonsei prognosis prediction model using Cox regression. Woo Jin Hyung

164

Incidence of brain metastasis from esophageal cancer. Jonathan Ben Ashman

165

Lymph node metastasis in gastric cancer: Location of positive station to predict survival after preoperative therapy. Naruhiko Ikoma

166

Comparative outcomes of minimally invasive and robotic-assisted esophagectomy. Kenneth L Meredith

167

Retrospective analysis of neoadjuvant chemoradiotherapy with carboplatin/ paclitaxel versus FOLFOX in newly diagnosed esophageal or junctional cancers: A single instituition experience. Ranjit Nair

168

The efficacy and feasibility of weekly 5-FU and cisplatin based radical concurrent chemoradiation therapy(CRT) in patients with esophageal cancer. Joon Won Jeong

169

Role of surgery for gastric cancer with liver limited multiple metastases. Hiromichi Shirasu

170

Risk factors of lymph node metastasis in undifferentiated early gastric cancers. Il Kim

171

One-dimensional and two-dimensional tumor size measurement for prediction of lymph node metastasis in differentiated early gastric cancer with minute submucosal invasion. Tae Jun Kim

172

Dosimetric effects of deep inspiration breath hold for radiation treatment of esophageal cancer based on tumor location. Kaleigh Doke

173

Clinical outcomes of elderly patients with esophageal cancer treated with chemoradiotherapy in the modern era. Cai Xu

174

Interim FDG-PET imaging during neoadjuvant chemoradiotherapy for esophageal cancer: Correlation with pathologic response. Daniel Tandberg

175

Analysis of tumor immune protein expression and clinical outcomes in gastric adenocarcinoma. Andrew M. Blakely

177

Predictive value of Surgical Apgar Score for long-term outcome in patients with gastric cancer. Masanori Tokunaga

178

Gastrointestinal stromal tumors (GISTs) of the esophagus and gastroesophageal junction (GEJ). Andrew M. Briggler

179

Short and long-term effects of two different surgery approaches for remnant gastric cancer. Lin Chen

180

Adjuvant chemotherapy and outcomes in esophageal carcinoma. Nadia Saeed

181

Efficacy and safety of endoscopic submucosal dissection in elderly patients with esophageal squamous cell carcinoma. In Seub Shin

182

The impact of new-onset atrial fibrillation on short- and long-term outcomes after esophagectomy for esophageal cancer. Eisuke Booka

183

Gastric linitis plastica: Have we moved beyond surgical palliation? Katherine Woo

184

Analysis of predictive factors of ramucirumab plus paclitaxel for advanced gastric cancer. Naoki Fukuda

185

Severe toxicity risk factor analysis of salvage radiotherapy for oligo-recurrence in the lymph nodes (LN) of esophagus carcinoma: From multi-institutional retrospective study. Toshihiko Matsumoto

186

Effect of extending the original eligibility criteria for the “CROSS” neoadjuvant chemoradiotherapy on toxicity and survival in esophageal cancer. Jan-Binne Hulshoff

187

Iron deficiency anemia in gastric cancer: A single site retrospective cohort study. Grace Tang

188

Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre. Akina Natori

189

Risk factor analyses of severe cicatricial stricture after chemoradiotherapy for stage II/III (T3) esophageal carcinoma. Natsuko Tsushita

190

Association between markers of malnutrition (MN) and toxicity (T) during neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer (EC). Rishi Jain

191

Outcomes of ERCC1 high locally advanced esophageal cancer patients treated with non-platinum vs platinum based CRT. Meera Yogarajah

192

The impact of dose modification or termination of S-1 as adjuvant therapy on survival of locally advanced gastric cancer underwent curative gastrectomy. Takeshi Kawakami

193

The impact of the extent of gastric resection on advanced gastric cancer treated with systemic chemotherapy. Yusuke Sasaki

194

Recurrence patterns in esophageal cancer patients undergoing curative trimodality therapy. Edwin Chan

195

Impact of race on gastric adenocarcinoma outcomes in a multiracial population. Jared David Acoba

196

Long-term survival in 101 metastatic gastroesophageal cancer (mGEAC) patients eventually treated with consolidative local therapy. Dilsa Mizrak Kaya

197

Comparison of neoadjuvant chemoradiation versus peri-operative chemotherapy for adenocarcinoma of the distal esophagus and gastroesophageal junction. Matthew Bertke

198

Retrospective study of ramucirumab in patients with advanced gastric cancer. Daisuke Sakai

199

Evaluation of hepatectomy, radiofrequency ablation, and transarterial chemoembolization for the local treatment of liver metastases in gastric cancer patients. Lin Chen

200

Application of very low dose-rate brachytherapy in gastrointestinal cancer. Arnold M. Herskovic

201

Neoadjuvant chemoradiotherapy (NCRT) compared with chemotherapy (NCT) in locally advanced squamous-cell cancer of the esophagus. Xue Li

202

CUSUM analysis of mortality following esophagectomy to allow for identification and intervention of quality problems. Patrick James McLaren

203

Toxicity and survival in older versus younger esophageal cancer (EC) patients (pts) treated with neoadjuvant chemoradiotherapy (nCRT). Rishi Jain

204

Predictive factors for long-term survival after conversion surgery for unresectable gastric cancer: A retrospective analysis. Tamotsu Sagawa

205

Predictors of pathological response and tumor regression following neoadjuvant therapy in advanced gastric cancer patients. Ulysses Ribeiro

206

Clinicopathologic differences and survival of Hispanics (H) versus Non-Hispanic Whites (NHW) with gastric cancer (GC) at a Majority Minority Cancer Center in South Texas. Cesar Ivan Barron

208

The usefulness of Roux-en-Y reconstruction with aboral pouch following total gastrectomy for gastric cancer. Shirou Iwagami

209

Entral feeding tube insertion after esophagectomy: Technique via transgastric conduit or transduodenal. Takashi Ogata

210

Comparison of cisplatin induced nephrotoxicity with short hydration or conventional hydration in gastric cancer: A retrospective study. Takeshi Aoyama

211

Phase II, prospective, single-arm, single-institutional, open-label clinical trial on laparoscopic sentinel node navigation surgery in early gastric cancer. Do Joong Park

90

Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303). Yoshinari Mochizuki

91

Outcomes of adjuvant chemotherapy after neoadjuvant chemoradiotherapy for esophageal cancer. Ravi Shridhar

92

Trastuzumab beyond first progression in cases of HER2-positive advanced gastric or gastro-esophageal junction cancer: Initial results from KSCC1105, a trastuzumab observational cohort study. Akitaka Makiyama

93

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: A multicenter AGEO study. Juliette Palle

94

NESC multicenter phase II trial in the preoperative treatment of gastric adenocarcinoma with chemotherapy (docetaxel-cisplatin-5FU + lenograstim) followed by chemoradiation (RTCT) based 5FU and oxaliplatin and surgery. Laurent Mineur

95

Phase II study of intraperitoneal paclitaxel plus S-1/paclitaxel for gastric cancer with positive peritoneal cytology: CY-PHOENIX trial. Masaki Aizawa

96

Adjuvant chemotherapy and overall survival in patients with node positive esophageal adenocarcinoma treated with neoadjuvant therapy and esophagectomy: A retrospective analysis using the National Cancer Database. Gaurav Ajmani

97

A phase II study to examine the effectiveness of nutritional support with elemental diet for stage II/III gastric cancer patients receiving adjuvant chemotherapy with S-1 (OGSG 1108). Junji Kawada

98

Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis (PIPAC-GA1). Florian Struller

99

A phase II trial of neoadjuvant chemotherapy with docetaxel/cisplatin/capecitabine in thoracic esophageal squamous cell carcinoma. Xiaobin Wu

TPS216

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Johanna C. Bendell

TPS217

T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. Taito Esaki

TPS218

A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer. Daniel V.T. Catenacci

TPS219

Combining pembrolizumab and palliative radiotherapy in gastroesophageal cancer to enhance anti-tumor T-cell response and augment the abscopal effect. Joseph Chao

TPS220

iMYC: Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified oesophagogastric carcinoma. Michael Davidson

TPS221

Exploratory study of intraperitoneal paclitaxel plus mFOLFOX6 for gastric cancer patients with peritoneal metastasis and inadequate oral intake. Shuntaro Yoshida

TPS222